Published Online: 2025 May 20



## The Similarity of a Critical Quality Study Among the Ciplukan Extract Capsule from A Laboratory Setting and a Pilot Scale in a Partner Industry

Yoga Windhu Wardhana (b) <sup>1,\*</sup>, Raden Bayu Indradi (b) <sup>2</sup>, Ade Zuhrotun (b) <sup>2</sup>, Rini Hendriani (b) <sup>3</sup>, Enny Rohmawaty (b) <sup>4</sup>, Winda Saragih (b) <sup>5</sup>, Savira Ekawardhani (b) <sup>6</sup>, Hesti Lina Wiraswati (b) <sup>6</sup>, Sumartini Dewi (b) <sup>7</sup>

<sup>1</sup> Department of Pharmaceutics and Pharmaceutical Technology, Dosage Form Development Research Center, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia

<sup>2</sup> Department of Biological Pharmacy, Center for Herbal Studies, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia

<sup>3</sup> Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia

<sup>4</sup> Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia
<sup>5</sup> Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia

<sup>6</sup> Department of Biomedical Science, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia

<sup>7</sup> Division Rheumatology, Department of Internal Medicine, Immunology Study Center, Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia

\* Corresponding Author: Department of Pharmaceutics and Pharmaceutical Technology, Dosage Form Development Research Center, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia. Email: y.w.wardhana@unpad.ac.id

Received: 22 September, 2024; Revised: 4 May, 2025; Accepted: 11 May, 2025

## Abstract

**Background:** Differences in pharmaceutical product processing and equipment between laboratory development and industrial scale-up can result in dramatically variable quality. Therefore, the quality similarities across pharmaceutical dosage forms must be tested at several facilities. Similarities in the quality of dosage forms for pharmacological treatment derived from herbal ingredients from development and production scale are often overlooked, and no one has published them yet.

**Methods:** A two-level factorial experimental design was used in the laboratory for formulation optimization, with variations in the composition of colloidal silicon dioxide and starch glycolate salts. Quality responses included loss on drying (LOD), flowability, angle of repose, uniformity of capsule weight, and disintegration time. The same responses as the performance of similarity attributes were also evaluated on pilot-scale items from partner businesses.

**Results:** The overall quality response of the tested product met the standards for fine granules and capsules. The composition with the highest attractiveness, according to the program, was F4 at 0.686, based on a pilot-scale formulation at partner industrial facilities. According to a Jaccard similarity of 0.88, the quality test results were quite comparable. A total plate number test was performed to assess the safety of microbiological contamination throughout the processing of all goods,

yielding a result of 7.07 × 10<sup>4</sup>, which is still in conformity with the standards of the Indonesian Food and Drug Administration (FDA), namely 10<sup>7</sup>.

(FDA), namely 10<sup>°</sup>.

**Conclusions:** The Jaccard similarity index for capsule manufacture at two different manufacturing sites is 0.88, indicating an excellent resemblance. This suggests that the process may be repeated in larger quantities.

*Keywords:* Ciplukan Capsule, Formulation Development, Pilot-Scale Product, Similarity Index

## 1. Background

The medicinal properties of ciplukan (*Physalis angulata* L.) have been widely studied for their anti-

inflammatory, immunomodulatory, antibacterial, anticancer, and antifibrotic properties (1). A more thorough study by Rohmawaty et al. (2) demonstrated that the 70% ethanol extract of ciplukan, fractionated

Copyright © 2025, Wardhana et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Wardhana Y W, Indradi R B, Zuhrotun A, Hendriani R, Rohmawaty E, et al. The Similarity of a Critical Quality Study Among the Ciplukan Extract Capsule from A Laboratory Setting and a Pilot Scale in a Partner Industry. J Rep Pharm Sci. 2025; 13 (1): e154434. https://doi.org/10.5812/jrps-154434.

into ethyl acetate, exhibited a significant anti-fibrosis effect, with therapeutic doses starting from 2.22 mg to lower serum alanine aminotransferase levels in rats (2). This indicates that the 70% ethanol extract of ciplukan has great potential for development into standardized herbal medicines or even phytopharmaceuticals. If developed, it could be conveniently available as a solid dosage form, such as a capsule. Similar to other pharmaceutical preparations, quality capsules must ensure homogeneity in active ingredient content, ease of production, and effective disintegration in the digestive tract. To achieve this, specific excipients are required according to their function.

The general challenge in scaling up herbal formulations from the laboratory to industrial production is that larger quantities with different energy strengths can affect quality. Therefore, a method to ensure that critical quality attributes (CQA) are maintained is necessary. Formulation development should lead to quality by design, necessitating the study of the effect of excipient function and composition variation on the expected quality response (2, 3). Among formulation designs, the two-level factorial design is frequently used due to its adequate yield precision. In a two-level factorial design, only two main points of the independent variable (lowest and highest) are tested to understand how each factor influences the dependent variable and how these factors interact, allowing for concise conclusions (3-5).

Recommendations for good quality design formulations developed in the laboratory may change when scaled up in industries with different facilities. Therefore, it is necessary to test the similarity of critical quality attributes between the two products. The criteria chosen to compare product quality from both facilities, which are most critical and affect dose homogeneity and bioavailability, are loss on drying (LOD), flowability, and disintegration time. These parameters will be fixed variables checked for similarity. Similarity is calculated using the Jaccard similarity index formula, which is based on a comparison between the intersections of the two data groups and their union (6). The Jaccard similarity coefficient measures the similarity between sample sets. It is the ratio between the intersection size and the union size of the sample set. The Jaccard Similarity Index method was chosen because it is simple to calculate, unaffected by the size of the data set, reliable for determining similarity when sets have different sizes, and can be used to compare the similarity of any type of data (7).

## 2. Objectives

This article will facilitate the handling of traditional medical goods derived from extracts in accordance with regulatory requirements, which have been challenging to achieve process validation, particularly during the transition from laboratory to production scale.

## 3. Methods

## 3.1. Materials

The entire *Physalis angulata* Linn., excluding the radix component, was collected from various regions in West Java, Indonesia, between December 2019 and February 2020. The Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran assessed the harvest samples. Excipients for formulation, such as colloidal silicon dioxide, microcrystalline cellulose pH 102, lactose, benzoic acid, starch glycolate salt, and capsule size no. 1, were purchased from Bratachem, Inc. Reagents, including aluminum chloride, sodium acetate, quercetin, and solvents such as acetone, ethanol, and toluene, were purchased from Sigma-Aldrich (Merck) with grade analysis.

#### 3.2. Preparation of Physalis angulata Linn. Ethanol Extract

The extraction method used was cold maceration, which involved stirring a solvent multiple times at room temperature. Ciplukan herbs (excluding roots) were suspended in 70% ethanol for 3 × 24 hours. A rotary vacuum evaporator was used to concentrate the filtrate.

#### 3.3. Extract Standardization

To evaluate quality, standardization was conducted using evaluations from the Indonesian herbal pharmacopoeia, including organoleptic properties, total ash content, acid-insoluble ash content, watersoluble extract content, ethanol-soluble extract content, and drying shrinkage (8, 9). Analyzing these indicators provides a general idea of the overall chemical component content in a herbal material.

# 3.4. Thin-layer Chromatography Analysis of Treatment Outcomes

Using a toluene-acetone-acetic acid (6:6:0.05) solution, a mixture containing the temperature and pH test results and controls was prepared and spread over silica gel F254 on the thin-layer chromatography (TLC) plate, then eluted. The test solution was prepared by combining an extract solution with a concentration of 15% in 70% ethanol and a quercetin solution as a reference with a concentration of 0.3% in 96% ethanol.

The TLC plate was removed and allowed to dry naturally. It was then examined under UV light at 254 and 366 nm. To determine the Rf value, the areas were sprayed with LP citronella detection, heated at 100°C for 5 - 10 minutes, and then evaluated again under 366 nm UV light.

#### 3.5. Flavonoid Total Content as Quercetin

The test was conducted by weighing 10 - 20 capsules, each equivalent to 0.2 grams of extract. The test solution was prepared by diluting the sample in 25 mL of alcohol and extracting it for 1 hour using a magnetic stirrer. The solution was then filtered into a 25 mL volumetric flask, and the filter paper was rinsed with ethanol P, with ethanol P added up to the mark. The reference solution was obtained by diluting 10 mg of quercetin in a 25 mL volumetric flask with ethanol P and further diluting to concentrations of 80, 75, 60, 50, and 40 ppm. The concentration was determined by pipetting 0.5 mL of the test solution, followed by the addition of 2.8 mL of water, 0.1 mL aluminum chloride (10%), 0.1 mL sodium acetate (1 M), and 1.5 mL of ethanol P. After shaking, the solution was allowed to stand at room temperature for 30 minutes. Blank solutions were prepared in the same manner, excluding the addition of aluminum chloride or the test solution. The solution was analyzed at a maximum absorption wavelength of 425 nm. The terms of acceptance require the level of active ingredients to be within the range of 90 - 110% of the label statement (10).

#### 3.6. Formulation by Two Levels Factorial Design

Formulation optimization was performed using a two-level factorial design with three replications as input factors in experiments using Design Expert version 11. Colloidal silicon dioxide was used as an adsorbent dryer with values ranging from 3% (low) to 10% (high), and starch glycolate salt was used as a disintegrator with values ranging from 2% (low) to 8% (high). Excipient variations were based on the ability of these materials, commonly used in granulation, to enhance the flowability and compressibility of granules as well as their dispersing ability. The number of variations was adjusted according to the handbook of pharmaceutical excipients. The three types of responses included were LOD, flow rate (g/s), and disintegration time (s). The recommendations from the two-level factorial design resulted in four formulas that were tested for response in three repetitions (Tables 1 and 2).

3.7. Similarity Study Between Capsule Products

Jaccard similarity is used for its convenience; the concept involves directly comparing the intersection of two data groups with their union. The Jaccard similarity equation is presented as follows.

$$sim~(u,v) jaccard = rac{|Iv~\cap Iu|}{|Iv~\cup Iu|}$$

This equation determines the level of similarity between the two variables tested (11).

$$J(S,T) = \frac{\sum_{k} \min(Sk,Tk)}{\sum_{k} \max(Sk,Tk)}$$

#### 3.8. Evaluation of Granules and Capsules

The resulting granules were evaluated for LOD, flowability, angle of repose, capsule weight uniformity, and disintegration time of the capsules. The LOD was calculated by determining the water content of the extract using 10 g of granules heated at 70 - 80°C. The LOD requirement was 2 - 5%.

#### 3.8.1. Flowability and Angle of Repose

The diameter and height of the granule cone were measured using a flow tester with 25 g of granules flowing through the funnel. The flow rate and angle of repose were calculated using the following formula:

$$Flow rate = \frac{Powders \ weight \ (g)}{Flow \ time \ (s)}$$
$$\tan \alpha = \frac{H \ (height \ in \ cm)}{R \ (radius \ in \ cm)}$$

The values of the acceptance requirements can be seen in Tables 3 and 4.

## 3.8.2. Capsule Weight Uniformity

Weight homogeneity was assessed by individually weighing 20 capsules, then removing their contents and weighing the empty capsule shells. The total weight of the capsule contents was calculated, and the average weight of each capsule's contents was determined. The percentage difference in the weight of the contents of each capsule compared to the average weight cannot exceed the limits specified in column "A," and for every 2 capsules, it cannot exceed the limits specified in column "B" (8, 9).

$$Deviation (\%) = rac{(Averages of a capsule weight induvidually)}{(Averages of a capsule weight induvidually)} imes 100\%$$

$$Averages \ of \ all \ capsule$$

Table 1. The Composition of Adsorbent Formulation in Laboratory Development					
Ingredients	Amount/Caps (mg)				A
	F1	F2	F3	F4	Annotation
1. Ciplukan extract	125.0	125.0	125.0	125.0	Active compound
2. Microcrystalline cellulose	57.8	57.8	57.8	57.8	Binder, adsorbent
3. Colloidal silicon dioxide	12.5	12.5	3.8	3.8	Adsorbent

Table 2. The Composition of Capsule Dosage form in Laboratory Development

Ingredients		Amount/	Annotation		
	Fi	F2	F3	F4	Aimotation
1. Extract Powder	190.0	196.5	190.4	196.7	Active compound
2. Na. starch glycolate	5.8	5.8	23.2	23.2	Disintegrant
3. Benzoic acid	0.029	0.029	0.029	0.029	Preservative
4. Lactose		Ad 290			Filler

Table 3. Flowability (Flow Rate) Acceptance Conditions		
Flow Rate (g/s)	Means	
>10	Free flowing	
4-10	Easy flowing	
1.6 - 4	Cohesive	
<1.6	Very cohesive	

The values of the acceptance requirements can be seen in Table 5.

#### 3.8.3. Disintegration Time Test

The disintegration time test was conducted using a disintegration tester by placing six capsules into each tube in a basket, beneath which was 10 mesh steel gauze, with an aqueous medium maintained at  $37 \pm 2^{\circ}$ C. The requirement for capsule disintegration time is that all capsules must disintegrate, except for a part of the capsule shell. If one or two capsules do not completely disintegrate, the test should be repeated with another 12 capsules; at least 16 of the 18 tested capsules must be completely disintegrated. The capsule disintegration time should not exceed 15 minutes.

#### 4. Results and Discussion

The yield of the ciplukan herb extract from the maceration method in 70% ethanol was 11.75%. The extract was obtained and examined for the suitability of the extract parameters based on the Republic of Indonesia herbal pharmacopoeia, and the results met the requirements (Table 6). Qualitative and quantitative

tests were conducted on several total flavonoids to determine the content responsible for the therapeutic effect. Qualitative testing was performed using TLC with the standard flavonoid quercetin, as shown in Figure 1. The image shows that the stain results from the test sample (extract) and the working reference (quercetin) are at the same R<sub>f</sub> of 0.467, indicating that the extract contained a sufficient amount of flavonoids, similar to quercetin. For quantitative testing, according to the herbal pharmacopoeia guidelines, the total flavonoid content was determined for finished products (both laboratory and pilot-scale results from industrial partners) using the AlCl<sub>2</sub> reagent, and it was found that conformity to acceptance requirements was in the range of 90 - 110% (Figures 2 and 3).

Therefore, extracts that satisfy these requirements can be used for capsule preparation. A two-level factorial experimental design was employed for the laboratory development of capsule formulations. The input variables included variations in the composition of colloidal silicon dioxide as an adsorbent for the dried thick extract (Table 1) and starch glycolate salt as a disintegrant within the capsules (Table 2). The response

Table 4. Requirements for Acceptance of Angle of Repose		
Angle of Repose	Means	
25-30	Excellent	
31-35	Good	
36-40	Fair	
41 - 45	Poor	
46 - 55	Poor	
56 - 65	Very poor	
> 66	Extremely poor (cohesive)	

Table 5. The Acceptance Requirements of Capsule Weight Uniformities (12)				
Canculas Waight Avarage	Differences Between Capsules (%)			
Capsules weight Average	A	В		
≤120 mg	10	20		
≥120 mg	7.5	15		

Table 6. Comparison of Standardized Extract Parameters Among Physalis angulata Linn. vs. Physalis minimae (from Indonesian Herbal Pharmacopoeia)<sup>a</sup>

Evaluated Parameter of Extract	Physalis angulata Linn. Herbs <sup>b</sup>	Physalis minimae Leaves (from FHI) <sup>c</sup>
Specific parameters		
Organoleptic		
Water soluble extract content	27.70	> 8.10
Ethanol soluble extract content	7.21	> 2.80
Total flavonoid content (with quercetin as standard)	0.82	> 0.58
Physalin A	0.97	-
Withanolid A	0.31	-
Gallic acid	0.26	-
Saponin	2.58	-
Non-specific parameters		
Density of ethanol extract	1.02	-
Water content	10.00	<10
Loss on drying	9.53	<10
Total ash content	17.14	-
Acid insoluble ash content	4.83	-
Extract rendement	13.70	> 9.6

<sup>a</sup> Values are expressed as %.

<sup>b</sup> Dark greenish brown viscous extract, very thick, smells of extract.

<sup>c</sup> Extract thick, dark brown, and bitter taste.

to this variability was assessed by evaluating the quality of LOD, flowability, angle of repose, compressibility, and disintegration time. All parameters, except for the angle of repose, were entered into the Design Expert version 11 software, which recommended performing four variations of this formula. The optimization results provided a mathematical equation regarding the influence of composition variations on each response, where the P-value for assessing the overall quantitative flowability was fulfilled, while the angle of repose served as a qualitative assessment influencing it.

The disintegration time responses are < 0.05, except for the LOD response, which is > 0.05 (Tables 7 and 8). This indicates that compositional variations do not affect LOD, whereas the other responses were strongly influenced by variations in the two excipients. This can



Figure 1. The thin layer chromatography (TLC) profile with the standard flavonoid quercetin in visible light (A); UV 254 nm (B); and UV 366 nm (C). Q: Quercetin; S: Sample.



#### Angle of repose (°)

Figure 2. The angle of repose results from each formula

be observed in the contour plots, where the color for LOD does not differ, whereas for the other responses, there is a color shift. The difference in color indicates that the red color of the response is stronger, while the blue color indicates a lower response value. The statistical recommendations from the experimental design software yielded F4 (composition of 3% colloidal silicon dioxide and 2% glycolate starch salt) with a desirability value of 0.686. It can be seen that F4 tends to be closer to the red color for both responses (flowability and disintegration time) than the other formulas (Figure 4).

Considering the results of formulation development and the availability of ingredients in the partner pharmaceutical industry, there are changes in excipients, as shown in Table 9. The difference in the use



Figure 3. The total flavonoid contents between finished products

Excipient	Flowability (g/s)	LOD (%)	Disintegration Time (s)
1. Colloidal silicon dioxide	38.98	0.2133	92.96
2. Na. starch glycolate	9.21	0.0001	53.34
3. Premix of colloidal silicon dioxide-Na. starch glycolate <sup>a</sup>	0.65	0.0481	257.61
Abbraviation: IOD, loss on draing			
Abbreviation: LOD, loss on drying.			
<sup>a</sup> P-value > 0.05.			

Excipient	Flowability	LOD	<b>Disintegration Time</b>
1. Model	0.0018	0.4856	0.0002
2. Colloidal silicon dioxide	0.0005	0.1777	0.0031
3. Na. starch glycolate	0.0255	0.9714	0.0132
4. Premix of colloidal silicon dioxide-Na. starch glycolate <sup>a</sup>	0.4877	0.5026	0.0001
Abbreviation: LOD, loss on drying.			
<sup>a</sup> P-value > 0.05.			

of these excipients resulted in a variation in the final weight of the capsules between the two different facilities. Thus, ensuring similarity in quality becomes more critical due to these differences. From a quality comparison with pilot-scale products, the closeness of quality results is seen in F3 and F4, with the Jaccard similarity index showing a similarity value of 0.88 (Figure 5), indicating that capsules from the laboratory and pilot scales have a fairly good resemblance. This suggests that the variation in the usage of excipients between the two facilities is not significant, and the composition of the formula from partner industries can be produced in larger batches. The dissimilarities in LOD may occur due to environmental factors, excipients, and measurement instruments used in the two locations, but for herbal preparations, this small difference in drying decimation does not have a major impact on overall quality. The quality of microbial contamination of the capsules from both products (laboratory and pilot scale) was also examined, as shown in Table 10, by calculating the average total plate number of  $7.07 \times 10^4$ ,



Figure 4. The contour plots of each excipient contribute to quality responses with A-coloidal silicon dioxide (A) and B-Na. starch glycolate (P) where are the equations for: Loss on drying (LOD) = 0.946032 - 0.007937A + 0.040317P - 0.006032AP; flowability = 13.24651 - 0.404148A - 0.147912P - 0.022163AP; and disintegration time = 94.06111 - 1.41111A - 3.57103P + 0.41270AP

Table 9. The Composition of Capsule Dosage form in Pilot-Scale Industry				
Ingredients	Amount/Caps (mg)	Annotation		
Adsorbent				
Ciplukan extract	125.0	Active compound		
Amylum maydis	118.8	Binder, adsorbent		
Colloidal silicon dioxide	6.3	Adsorbent		
Capsule filler				
Lactose	150.0	Filler, disintegrant		





Figure 5. The Jaccard similarity index between lab and pilot-scale products

which is still in line with the Indonesian Food and Drug Administration (FDA) requirements of 10<sup>7</sup> (3).

## 5. Conclusions

The yield of the ethanol extract of ciplukan complies with the requirements of the Indonesian herbal

pharmacopoeia, allowing it to be prepared into capsule dosage forms. The results of similarity testing between capsule production at two facilities with different formulations show a Jaccard similarity index of 0.88, indicating a fairly good similarity. The results of the microbial contamination test, by calculating the

Table 10. The Average Total Plate Number				
Variables	Cup 1	Cup 2	Bacteria Amount	
Controlled	0	-	0	
10 <sup>-1</sup>	0	0	0	
10 <sup>-2</sup>	25	1	2.5×10 <sup>3</sup>	
10 -3	0	1	10 <sup>3</sup>	
10 <sup>-4</sup>	15	6	$1.5 \times 10^{5}$	
10 -5	2	1	$2 \times 10^{5}$	

average total plate number, were found to meet the requirements of the Indonesian FDA of 10<sup>7</sup>, with an average total plate number of  $7.07 \times 10^4$ . Thus, the composition of the formula from the partner industry can be continued in the production of larger batches.

## Acknowledgements

Appreciate with fully grateful to the Directorate of Research and Community Service who has helped so that the Education Fund Management Institution -Ministry of Finance RI (LPDP) is willing to fund it with RISPRO scheme. We also thank to Abdullah Thirazuddin Hasyim who helped a lot in data collection.

## Footnotes

Authors' Contribution: Conceptualization: Y. W. W. and S. D.; Data curation: Y. W. W., R. B. I, A. Z., R. H., E. R., and W. A. M. S.; Formal analysis: Y. W. W., S. D., R. B. I., and A. Z.; Funding acquisition: S. D. and W. A. M. S.; Investigation: Y. W. W., R. B. I., and Z. A.; Methodology: Y. W. W., A. Z., S. E., and H. L. W.; Project ad-ministration: W. A. M. S. and E. R.; Resources: S. D., A. Z., R. B. I., and Y. W. W.; Software: Y. W. W.; Supervision: Y. W. W., A. Z., and R. B. I.; Validation: Y. W. W., S. D., A. Z., and R. B. I.; Visualization: Y. W. W. and R. B. I.; Writing–original draft: Y. W. W., S. D., A. Z., R. B. I., and R. H.; Writing-review and editing: Y. W. W., S. D., A. Z., R. B. I., and R. H. All authors have read and agreed to the published version of the manuscript.

**Conflict of Interests Statement:** The authors declared no conflict of interests.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Funding/Support: Education Fund Management Institution - Ministry of Finance RI (LPDP) is willing to fund it with RISPRO scheme.

#### References

- 1. Kusumaningtyas R, Laily N, Limandha P. Potential of Ciplukan (Physalis Angulata L.) as Source of Functional Ingredient. Procedia *Chemistry*. 2015;14:367-72. https://doi.org/10.1016/j.proche.2015.03.050.
- Rohmawaty E, Rosdianto AM, Usman HA, Saragih WAM, Zuhrotun A, 2. Hendriani R, et al. Antifibrotic effect of the ethyl acetate fraction of ciplukan (Physalis angulata Linn.) in rat liver fibrosis induced by Pharm Sci. 2021;11(12):175-82. CCI4. J Appl https://doi.org/10.7324/japs.2021.1101217.
- 3. Balingui CF, Nkenmogne IE, Ngassoum MB, Talla E. Optimisation of Encapsulation by Complex Coacervation of Phenolic Compounds from Propolis with Triumfetta cordifolia Gum and Kinetic Study. Trop J Nat Prod Res. 2023;7(3):2605-10. https://doi.org/10.26538/tjnpr/v7i3.21.
- 4. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771-83. [PubMed ID: 24854893]. [PubMed Central ID: PMC4070262]. https://doi.org/10.1208/s12248-014-9598-3.
- 5. Ioffe S. Improved Consistent Sampling, Weighted Minhash and L1 Sketching. 2010 IEEE International Conference on Data Mining. 13-17 December 2010; Sydney, NSW, Australia. 2010. p. 246-55.
- 6. Montgomery DC. Design and Analysis of Experiments. 8th ed. New York: John Wiley & Sons; 2013.
- 7. Zahrotun L. Comparison Jaccard similarity, Cosine Similarity and Combined Both of the Data Clustering With Shared Nearest Neighbor Method. Comput Eng Appl J. 2016;5(1):11-8. https://doi.org/10.18495/comengapp.v5i1.160.
- 8. Food and Drug Administration Indonesia. [Regulation of the Food and Drug Supervisory Agency Number 32 of 2019 concerning Safety and Quality Requirements for Traditional Medicines]. 2019. ID. Available from: https://peraturan.bpk.go.id/Details/285067/peraturan-bpomno-32-tahun-2019.
- 9. Indonesian Ministry of Health. [Indonesian Herbal Pharmacopoeia]. 2nd ed. Jakarta: Indonesian Ministry of Health; 2017. ID.
- Fadillah A, Rahmadani A, Rijai L. Analisis Kadar Total Flavonoid dan 10. Uji Aktivitas Antioksidan Ekstrak Daun Kelubut (Passiflora foetida L.). Proc Mul Pharm Conf. 2017;5:21-8. https://doi.org/10.25026/mpc.v5i1.217.
- 11. Bag S. Kumar SK. Tiwari MK. An efficient recommendation generation using relevant Jaccard similarity. Inf Sci. 2019;483:53-64. https://doi.org/10.1016/j.ins.2019.01.023.
- 12. Indonesian Ministry of Health. [Indonesian Pharmacopoeia]. 6th ed. Jakarta: Indonesian Ministry of Heath; 2021. ID.